Cyclic guanosine monophosphate-specific phosphodiesterase (cGMP PDE)

Cyclic guanosine monophosphate (cGMP) phosphodiesterases are a specialized group of enzymes that catalyze the hydrolysis of the second messenger cGMP into inactive 5'-GMP [UniProt: O76074]. By controlling the spatial and temporal levels of cGMP, these enzymes regulate critical physiological pathways, including nitric oxide-mediated vasodilation, smooth muscle relaxation, and phototransduction in the retina [PubMed: 15082007]. The family includes cGMP-specific isoforms such as PDE5, PDE6, and PDE9, as well as dual-specificity enzymes like PDE1, PDE2, and PDE3 [StatPearls: NBK526132]. PDE5 is the most prominent therapeutic target, particularly in the treatment of erectile dysfunction and pulmonary arterial hypertension, where its inhibition enhances cGMP-dependent signaling to improve blood flow [NIH: PubChem CID 5212]. PDE6 plays a vital role in the visual cycle, and its unintended inhibition by certain drugs can lead to visual side effects [PubMed: 11259592]. Emerging research also highlights the role of PDE9 in cognitive function and heart failure, making it a target for novel therapeutic development [PubMed: 26078471]. These enzymes are characterized by a conserved catalytic domain and regulatory domains that allow for feedback control and integration with other signaling pathways. Pharmacological modulation of cGMP phosphodiesterases remains a cornerstone of cardiovascular and urological medicine.

Other names

cGMP-specific phosphodiesterase3',5'-cyclic-GMP phosphodiesteraseGuanylate phosphodiesterasePDE5PDE6PDE9

Competitive inhibition of the catalytic site of the phosphodiesterase enzyme, preventing the hydrolysis of cyclic guanosine monophosphate (cGMP) to 5'-GMP, thereby prolonging the physiological effects of cGMP-mediated signaling pathways [StatPearls: NBK526132, PubMed: 15082007].